Abstract

Urinary incontinence afflicts up to 40% of adult women in the United States. Stress urinary incontinence (SUI) accounts for approximately one-third of these cases, precipitating ~200,000 surgical procedures annually. Continence is maintained through the interplay of sub-urethral support and urethral sphincter coaptation, particularly during activities that increase intra-abdominal pressure. Currently, surgical correction of SUI focuses on the re-establishment of sub-urethral support. However, mesh-based repairs are associated with foreign body reactions and poor localized tissue healing, which leads to mesh exposure, prompting the pursuit of technologies that restore external urethral sphincter function and limit surgical risk. The present work utilizes a human platelet-derived CD41a and CD9 expressing extracellular vesicle product (PEP) enriched for NF-κB and PD-L1 and derived to ensure the preservation of lipid bilayer for enhanced stability and compatibility with hydrogel-based sustained delivery approaches. In vitro, the application of PEP to skeletal muscle satellite cells in vitro drove proliferation and differentiation in an NF-κB-dependent fashion, with full inhibition of impact on exposure to resveratrol. PEP biopotentiation of collagen-1 and fibrin glue hydrogel achieved sustained exosome release at 37 °C, creating an ultrastructural “bead on a string” pattern on scanning electron microscopy. Initial testing in a rodent model of latissimus dorsi injury documented activation of skeletal muscle proliferation of healing. In a porcine model of stress urinary incontinence, delivery of PEP-biopotentiated collagen-1 induced functional restoration of the external urethral sphincter. The histological evaluation found that sustained PEP release was associated with new skeletal muscle formation and polarization of local macrophages towards the regenerative M2 phenotype. The results provided herein serve as the first description of PEP-based biopotentiation of hydrogels implemented to restore skeletal muscle function and may serve as a promising approach for the nonsurgical management of SUI.

Details

Title
Exosome biopotentiated hydrogel restores damaged skeletal muscle in a porcine model of stress urinary incontinence
Author
Rolland, Tyler J. 1 ; Peterson, Timothy E. 2 ; Singh, Raman Deep 1   VIAFID ORCID Logo  ; Rizzo, Skylar A. 3 ; Boroumand, Soulmaz 1 ; Shi, Ao 1   VIAFID ORCID Logo  ; Witt, Tyra A. 1 ; Nagel, Mary 1 ; Kisby, Cassandra K. 4   VIAFID ORCID Logo  ; Park, Sungjo 5 ; Rowe, Lois A. 6 ; Paradise, Christopher R. 7 ; Becher, Laura R. E. 7 ; Paradise, Brooke D. 7 ; Stalboerger, Paul G. 2 ; Trabuco, Emanuel C. 4 ; Behfar, Atta 8 

 Mayo Clinic Center for Regenerative Medicine, Van Cleve Cardiac Regenerative Medicine Program, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X) 
 Mayo Clinic Center for Regenerative Medicine, Van Cleve Cardiac Regenerative Medicine Program, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X); Mayo Clinic Department of Cardiovascular Medicine, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X) 
 Mayo Clinic Center for Regenerative Medicine, Van Cleve Cardiac Regenerative Medicine Program, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X); Mayo Clinic Medical Sciences Training Program, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X); Mayo Clinic Department of Molecular Pharmacology and Experimental Therapeutics, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X) 
 Mayo Clinic Division of Urogynecology, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X) 
 Mayo Clinic, Marriott Heart Disease Research Program, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X) 
 Mayo Clinic Center for Regenerative Medicine, Van Cleve Cardiac Regenerative Medicine Program, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X); Mayo Clinic, Marriott Heart Disease Research Program, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X) 
 Rion LLC, Rochester, US (GRID:grid.66875.3a) 
 Mayo Clinic Center for Regenerative Medicine, Van Cleve Cardiac Regenerative Medicine Program, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X); Mayo Clinic Department of Cardiovascular Medicine, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X); Mayo Clinic Department of Molecular Pharmacology and Experimental Therapeutics, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X); Mayo Clinic, Marriott Heart Disease Research Program, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X) 
Publication year
2022
Publication date
2022
Publisher
Nature Publishing Group
e-ISSN
20573995
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2719256903
Copyright
© The Author(s) 2022. corrected publication 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.